Absci (ABSI) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
12 Nov, 2026Executive summary
ABS-201 HEADLINE is progressing in Phase 1/2a for pattern hair loss; interim 13-week proof-of-concept data are expected in December 2026 and full 26-week data in early 2027.
A Phase 2 STORYLINE trial for endometriosis is planned for mid-2027; ABS-202 remains in nonclinical development.
Origin-1 generative design paired with lab-in-the-loop validation; the first two programs reached IND or foreign equivalent in ~2 years at ~$15M per program, versus cited industry averages of 4–6 years and >$50M.
Financial highlights
Q3 partner program revenue was $0.304M vs. $0.378M YoY; net loss was $33.3M vs. $28.7M.
Q3 R&D expense was $23.6M vs. $19.2M, mainly reflecting ABS-201 development; SG&A was $9.0M vs. $8.4M, primarily due to stock-based compensation.
9M revenue was $0.837M vs. $2.150M and net loss was $96.1M vs. $85.6M.
9M R&D expense rose 17% to $65.5M; operating expenses increased 10% to $100.8M, including SG&A of $27.3M and D&A of $8.1M.
Q3 diluted loss per share was $0.19 vs. $0.20; 9M diluted loss per share was $0.60 vs. $0.65.
Outlook and guidance
Interim 13-week HEADLINE data are expected in December 2026, including all 300 mg participants, most 600 mg participants and potentially an initial look at 1,200 mg; full 26-week data are expected in early 2027.
The 26-week results will inform Phase 3 dose selection; the 13-week interim is directional and not intended to change trial conduct.
STORYLINE is planned for mid-2027, subject to protocol finalization and regulatory clearance; planned enrollment is ~150 patients across ~10 or more countries.
Cash, cash equivalents and marketable securities of $173.7M are projected to fund operating plans into H2 2028.
R&D expense is expected to rise as HEADLINE, later-stage PHL trials, STORYLINE, other internal programs and platform investment advance.
Latest events from Absci
- ABS-201 advances toward pattern hair loss proof of concept as AI design capabilities expand.ABSI
Corporate presentation - ABS-201 readouts are approaching, with cash runway into H2 2028.ABSI
3rd Annual Guggenheim Healthcare Innovation Conference - ABS-201 advances with strong safety, high demand, and pivotal data expected in December.ABSI
Morgan Stanley 24th Annual Global Healthcare Conference - AI-driven clinical programs advance toward key milestones, supported by robust cash reserves.ABSI
H.C. Wainwright 28th Annual Global Investment Conference - AI-driven antibody platform advances novel therapies for hair loss and endometriosis, targeting large markets.ABSI
Corporate presentation - Positive interim data and strong cash reserves support continued clinical and pipeline progress.ABSI
Q2 2026 - AI-powered drug discovery advances key assets toward pivotal clinical milestones and partnerships.ABSI
Morgan Stanley 23rd Annual Global Healthcare Conference - AI-driven antibody platform advances ABS-101 and ABS-201 toward major clinical milestones.ABSI
R&D Day 2024 - Generative AI-driven antibody design, AMD partnership, and pipeline milestones set stage for 2025.ABSI
43rd Annual J.P. Morgan Healthcare Conference 2025